Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Vera Therapeutics Inc (NASDAQ: VERA) closed the day trading at $19.25 down -6.73% from the previous closing price of $20.64. In other words, the price has decreased by -$6.73 from its previous closing price. On the day, 1.75 million shares were traded. VERA stock price reached its highest trading level at $20.29 during the session, while it also had its lowest trading level at $19.19.
Ratios:
For a better understanding of VERA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.92 and its Current Ratio is at 16.92. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.16.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $49.Wolfe Research initiated its Outperform rating on February 04, 2025, with a $49 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 23 ’25 when ENRIGHT PATRICK G bought 209,393 shares for $20.87 per share. The transaction valued at 4,369,676 led to the insider holds 3,569,522 shares of the business.
ENRIGHT PATRICK G bought 40,607 shares of VERA for $907,635 on Jun 24 ’25. The Director now owns 3,596,593 shares after completing the transaction at $22.35 per share. On Feb 21 ’25, another insider, Fordyce Marshall, who serves as the PRESIDENT AND CEO of the company, sold 10,613 shares for $27.89 each. As a result, the insider received 296,032 and left with 213,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VERA now has a Market Capitalization of 1228606208 and an Enterprise Value of 749330560.
Stock Price History:
The Beta on a monthly basis for VERA is 1.17, which has changed by -0.46304047 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, VERA has reached a high of $51.61, while it has fallen to a 52-week low of $18.53. The 50-Day Moving Average of the stock is -15.66%, while the 200-Day Moving Average is calculated to be -38.39%.
Shares Statistics:
Over the past 3-months, VERA traded about 1.71M shares per day on average, while over the past 10 days, VERA traded about 1293440 shares per day. A total of 63.82M shares are outstanding, with a floating share count of 47.65M. Insiders hold about 25.28% of the company’s shares, while institutions hold 89.28% stake in the company. Shares short for VERA as of 1752537600 were 8238798 with a Short Ratio of 4.81, compared to 1749772800 on 9560166. Therefore, it implies a Short% of Shares Outstanding of 8238798 and a Short% of Float of 14.89.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Vera Therapeutics Inc (VERA) reflects the combined expertise of 2.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.11, with high estimates of -$1.0 and low estimates of -$1.22.
Analysts are recommending an EPS of between -$4.03 and -$4.44 for the fiscal current year, implying an average EPS of -$4.24. EPS for the following year is -$3.1, with 6.0 analysts recommending between -$2.28 and -$3.72.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $35.4M in the next fiscal year. The high estimate is $63.54M and the low estimate is $2.57M.
